Atox Bio Publishes Data Demonstrating The Broad Therapeutic Effect Of Its Flagship Pr

tD33NAt

Active member
Mar 24, 2008
12,519
0
36
Atox Bio announced new data in an animal model of necrotizing soft tissue infection (NSTI), commonly known as "flesh eating bacteria" demonstrating that administration of a single dose of AB103, given several hours after infection even without any antibiotics, increased survival in animals, and reduced tissue necrosis, inflammation and bacterial burden at the site of infection without compromising the immune response. NSTI or flesh eating bacteria is a life-threatening bacterial infection with significant morbidity and no currently approved therapies...
S46Ria629Z8


More...
 
Back
Top